Literature DB >> 16611119

Antiviral therapy targeting viral polymerase.

Ching-Hsiu Tsai1, Pei-Yu Lee, Victor Stollar, Mei-Ling Li.   

Abstract

Viral DNA and RNA polymerases are enzymes, which are responsible for copying the genetic materials of viruses and are therefore central components in the life cycles of viruses. The polymerases are essentially required for the replication of viruses. The reverse transcriptase (RT) of the retroviruses and the hepadnaviruses is the sole viral enzyme required for the synthesis of DNA from viral RNA. Viral polymerases are therefore an extremely favorable target for the development of antiviral therapy. The success of anti-HIV-1 therapy using inhibitors specifically targeting HIV RT suggests that other viral polymerases can be the valid molecular targets for the design of antiviral drugs. Intensive structural and functional studies of viral polymerases have been conducted and have opened new avenues for the development of more effective antiviral therapy. This review summarizes the insights gained from recent structural and functional studies of antiviral agents, which target viral polymerases. The primary focus will be on hepatitis C virus (HCV), herpesviruses, HIV, hepatitis B virus (HBV) and influenza virus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611119     DOI: 10.2174/138161206776361156

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  15 in total

Review 1.  Pandemic and seasonal influenza: therapeutic challenges.

Authors:  Matthew J Memoli; David M Morens; Jeffery K Taubenberger
Journal:  Drug Discov Today       Date:  2008-05-15       Impact factor: 7.851

Review 2.  Structure and function of Zika virus NS5 protein: perspectives for drug design.

Authors:  Boxiao Wang; Stephanie Thurmond; Rong Hai; Jikui Song
Journal:  Cell Mol Life Sci       Date:  2018-02-08       Impact factor: 9.261

3.  Induced intra- and intermolecular template switching as a therapeutic mechanism against RNA viruses.

Authors:  Richard Janissen; Andrew Woodman; Djoshkun Shengjuler; Thomas Vallet; Kuo-Ming Lee; Louis Kuijpers; Ibrahim M Moustafa; Fiona Fitzgerald; Peng-Nien Huang; Angela L Perkins; Daniel A Harki; Jamie J Arnold; Belén Solano; Shin-Ru Shih; Marco Vignuzzi; Craig E Cameron; Nynke H Dekker
Journal:  Mol Cell       Date:  2021-10-22       Impact factor: 17.970

4.  Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin.

Authors:  Armando Arias; Jamie J Arnold; Macarena Sierra; Eric D Smidansky; Esteban Domingo; Craig E Cameron
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

5.  Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT.

Authors:  Dwight V Nissley; Jessica Radzio; Zandrea Ambrose; Chih-Wei Sheen; Noureddine Hamamouch; Katie L Moore; Gilda Tachedjian; Nicolas Sluis-Cremer
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

6.  A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase.

Authors:  Sreedhar Chinnaswamy; Ian Yarbrough; Satheesh Palaninathan; C T Ranjith Kumar; Vinodhini Vijayaraghavan; Borries Demeler; Stanley M Lemon; James C Sacchettini; C Cheng Kao
Journal:  J Biol Chem       Date:  2008-04-28       Impact factor: 5.157

7.  Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.

Authors:  Valerie A Braz; Leslie A Holladay; Mary D Barkley
Journal:  Biochemistry       Date:  2010-01-26       Impact factor: 3.162

8.  HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection.

Authors:  Max von Kleist; Philipp Metzner; Roland Marquet; Christof Schütte
Journal:  PLoS Comput Biol       Date:  2012-01-19       Impact factor: 4.475

Review 9.  New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention.

Authors:  Gangqiang Guo; Lele Ye; Kan Pan; Yu Chen; Dong Xing; Kejing Yan; Zhiyuan Chen; Ning Ding; Wenshu Li; Hong Huang; Lifang Zhang; Xiaokun Li; Xiangyang Xue
Journal:  Front Cell Dev Biol       Date:  2020-05-22

Review 10.  SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.

Authors:  Ali A Rabaan; Shamsah H Al-Ahmed; Ranjit Sah; Ruchi Tiwari; Mohd Iqbal Yatoo; Shailesh Kumar Patel; Mamta Pathak; Yashpal Singh Malik; Kuldeep Dhama; Karam Pal Singh; D Katterine Bonilla-Aldana; Shafiul Haque; Dayron F Martinez-Pulgarin; Alfonso J Rodriguez-Morales; Hakan Leblebicioglu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-09-02       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.